There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Editas Medicine (EDIT – Research Report), Cogent Biosciences (COGT – Research Report) and Kura Oncology (KURA – Research Report) with bullish sentiments.
Editas Medicine (EDIT)
In a report released today, Rick Bienkowski from Cantor Fitzgerald reiterated a Buy rating on Editas Medicine, with a price target of $15.00. The company’s shares closed last Tuesday at $11.30.
According to TipRanks.com, Bienkowski is ranked #7872 out of 8414 analysts.
The word on The Street in general, suggests a Hold analyst consensus rating for Editas Medicine with a $13.91 average price target, which is a 44.9% upside from current levels. In a report released yesterday, Raymond James also upgraded the stock to Buy with a $17.00 price target.
See Insiders’ Hot Stocks on TipRanks >>
Cogent Biosciences (COGT)
Guggenheim analyst Charles Zhu reiterated a Buy rating on Cogent Biosciences today and set a price target of $26.00. The company’s shares closed last Tuesday at $12.84.
According to TipRanks.com, Zhu is a 1-star analyst with an average return of -5.6% and a 39.0% success rate. Zhu covers the Healthcare sector, focusing on stocks such as IDEAYA Biosciences, MacroGenics, and Xencor.
Cogent Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $22.50, which is an 82.5% upside from current levels. In a report issued on June 5, Piper Sandler also maintained a Buy rating on the stock with a $22.00 price target.
Kura Oncology (KURA)
Cantor Fitzgerald analyst Li Watsek reiterated a Buy rating on Kura Oncology today and set a price target of $30.00. The company’s shares closed last Tuesday at $12.83.
According to TipRanks.com, Watsek has 0 stars on 0-5 stars ranking scale with an average return of -13.4% and a 22.0% success rate. Watsek covers the Healthcare sector, focusing on stocks such as Oncternal Therapeutics, Corvus Pharmaceuticals, and Fate Therapeutics.
Kura Oncology has an analyst consensus of Strong Buy, with a price target consensus of $30.75, implying a 138.7% upside from current levels. In a report issued on May 29, Stifel Nicolaus also maintained a Buy rating on the stock with a $24.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on EDIT: